AstraZeneca announced a $2 billion investment to expand biologics manufacturing in Maryland, nearly doubling commercial biologics capacity at its Frederick campus and building a new clinical manufacturing facility in Gaithersburg. The company said the program will create and retain thousands of jobs and leverage AI, automation and data analytics. The expansion targets commercial supply resilience and onshoring of rare‑disease manufacturing capabilities, with both facilities expected to be operational by 2029. AstraZeneca described the investment as part of a broader $50 billion company commitment and emphasized its role in strengthening U.S. supply chains for advanced biologics. The build‑out signals continued large‑scale industrialization of cell and gene therapy supply chains and may accelerate partnerships, contract manufacturing demand and regional talent hiring in biologics process development and operations.